Introduction
Virus-infected mammalian cells are a battleground: cells mount antiviral defenses against the virus, and these defenses are countered by the infecting virus. The eventual outcome of this war is a major determinant of the pathogenesis of the virus infection.
In this minireview we will discuss the intracellular warfare between human influenza viruses and human cells. Influenza A and B viruses, two of the four influenza virus genera, cause widespread epidemics in humans (Lamb and Krug, 2001; Wright and Webster, 2001 ). Influenza A viruses, which have been isolated from a wide variety of avian and mammalian species, are responsible for the human pandemics that have caused high mortality rates, and the highly pathogenic virus that was transmitted from chickens to humans in Hong Kong in 1997 is an influenza A virus (Wright and Webster, 2001 ). Influenza B virus appears to infect only humans (Wright and Webster, 2001) , although influenza B virus has recently been isolated from seals (Osterhaus et al., 2000) . Both influenza A and B viruses contain eight genomic RNA segments, and most of the proteins encoded by the corresponding genomic RNA segments serve similar functions (Lamb and Krug, 2001 ).
We will focus solely on the role of one virus-encoded protein in the virus-cell war: the NS1 protein, which is encoded by the smallest genomic RNA segment of both influenza A and B viruses. This protein is designated as nonstructural (NS) because it is synthesized in infected cells, but is not incorporated into virions (Lamb and Krug, 2001) . The NS1 proteins of influenza A virus (NS1A protein) and influenza B virus (NS1B protein) share one function: the binding of double-stranded RNA (dsRNA) via their N-terminal RNA-binding domains (Hatada and Fukuda, 1992; Lu et al., 1995; Wang et al., 1999; Yuan et al., 2002) (Fig. 1) . The three-dimensional structure of the RNA-binding domain of the NS1A protein exhibits a novel dimeric six-helical chain fold Liu et al., 1997) that differs from that of any other known RNA-binding proteins in the structural database, including the dsRNAbinding domain (dsRBD) found in many cellular proteins (Ryter and Schultz, 1998; Ramos et al., 2000) . Computer modeling and mutagenesis experiments indicate that the RNA-binding domain of the NS1B protein exhibits a dimeric six-helical chain fold similar to that of the NS1A RNA-binding domain except that there are large loops between the three ␣-helices in each monomer (Wang et al., 1999; Yuan et al., 2002) . The RNA-binding domains of the NS1A and NS1B bind dsRNA with low affinity, approximately 5000-fold lower than the dsRBDs found in cellular proteins (McCormack and Samuel, 1995; Schmedt et al., 1995; Wang et al., 1999; Ohman et al., 2000; Tian and Mathews, 2001; Yuan et al., 2002) . All other functions of the NS1A and NS1B proteins differ markedly, as will be discussed later, resulting in major differences in the mechanisms by which these two proteins mediate viral countermeasures against cellular antiviral responses.
The first battle: the initial interferon-␣/␤ (IFN-␣/␤)-independent cellular antiviral response
Crucial cellular defenses against infection by mammalian viruses take place in initially infected cells prior to the synthesis of IFN-␣/␤ (Zhu et al., 1997; Maniatis et al., 1998; Navarro et al., 1998; Wathelet et al., 1998; Yoneyama et al., 1998; Preston et al., 2001; Simmen et al., 2001; Kim et al., 2002) . A major cellular response is the activation of transcription factors that con-trol the expression of antiviral genes. The initial activation of such transciption factors in response to virus infection is not mediated by IFN-␣/␤ and does not require viral protein synthesis Reich, 1993, 1995; Zhu et al., 1997; Navarro et al., 1998; Wathelet et al., 1998; Yoneyama et al., 1998; Boyle et al., 1999; Guo et al., 2000; Chin and Cresswell, 2001; Iwamura et al., 2001; Preston et al., 2001; Simmen et al., 2001; Kim et al., 2002; Noah et al., 2003) . Two transcription factors, interferon regulatory factor-3 (IRF-3) and IRF-7, are activated and combine with the transcriptional coactivators p300 and CREB-binding protein to form a transcription complex (Navarro et al., 1998; Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al., 1998; Preston et al., 2001; Kim et al., 2002) . This complex (virus-activated factor or VAF) binds to a subset of the IFN-␣/␤-stimulated response elements (ISREs) in the promoters of cellular genes, thereby inducing their transcription. Because some of the proteins encoded by these genes have antiviral activities (Boyle et al., 1999; Chin and Cresswell, 2001; Simmen et al., 2001; Kim et al., 2002) , this IFN-␣/␤-independent virus-induced activation of cellular transcription constitutes an early antiviral response of cells. Viruses need to mount countermeasures against such an early antiviral response to allow the virus to replicate (Chin and Cresswell, 2001) . This is the initial battle in the intracellular warfare between mammalian cells and many mammalian viruses.
Influenza A virus
As is the case with other mammalian viruses, infection of human cells with influenza A virus induces the IFN-␣/␤-independent activation of IRF-3 and transcription of ISREcontrolled cellular genes . Several different assays established that IRF-3 is activated Ehrhardt, C. and Ludwig, S., personal communication) . Cycloheximide does not inhibit IRF-3 activation , indicating that the synthesis of virus-encoded proteins is not required for this activation. In addition, IRF-3 activation occurs after infection of GRE cells , which do not produce IFN-␣/␤ (Bandyopadhyay et al., 1995) , indicating that activation is independent of IFN-␣/␤. A nuclear runoff transcription assay demonstrated that the transcription of the ISRE-controlled p56 gene is induced, thereby establishing that the IRF-3 which is activated after influenza A virus infection functions in transcription . In contrast to other viruses, this early IFN-␣/␤-independent activation of the synthesis of cellular antiviral pre-mRNAs after influenza A virus infection does not result in the production of mature antiviral mRNAs, indicating that the posttranscriptional processing of these cellular antiviral pre-mRNAs is inhibited . As a result, this early antiviral response of cells is effectively countered because the antiviral proteins encoded by these cellular genes are not synthesized. Consequently, influenza A virus wins the initial battle in the intracellular war with human cells.
A substantial body of evidence indicated that inhibition of the posttranscriptional processing of these cellular antiviral pre-mRNAs is most likely mediated by the viral NS1A protein. Transfection experiments and in vitro assays established that the NS1A protein inhibits the posttranscriptional processing of cellular pre-mRNAs by binding and inhibiting the function of two cellular proteins that are required for the 3Ј-end processing of cellular pre-mRNAs: the 30-kDa subunit of the cleavage and polyadenylation specificity factor (CPSF) and poly(A)-binding protein II (PABII) (Nemeroff et al., 1998; Chen et al., 1999; Chen and Krug, 2000; Li et al., 2001) . This inhibition of the cellular 3Ј-end processing machinery does not affect the addition of poly(A) tails onto viral mRNAs because the poly(A) tails of viral mRNAs are produced by the viral polymerase, and not by the cellular 3Ј-end processing machinery (Robertson et al., 1981; Poon et al., 1999) . The binding site in the NS1A protein for the cellular 30-kDa CPSF subunit is centered around amino acid 186 and the PABII-binding site is located in the 223-237 amino acid region (Li et al., 2001) (Fig. 1A) . Mutation of the NS1A-binding site for the 30-kDa CPSF subunit eliminates the ability of NS1A to inhibit 3Ј-end cleavage of pre-mRNAs in transient transfection assays, establishing that this NS1A-binding site is required for the inhibition of 3Ј-end processing of cellular pre-mRNAs (Li et al., 2001) . RNA binding by the NS1A protein plays no role in this inhibition. Several lines of evidence established that these transfection experiments and in vitro assays mirror events in infected cells: (i) the inhibition of 3Ј-end processing of newly synthesized cellular pre-mRNAs occurs in influenza A virus-infected cells (Chen et al., 1999; Shimuzu et al., 1999) ; (ii) this inhibition is mediated by the NS1A protein, as shown by using NS1A virus mutants (Chen et al., 1999; Shimuzu et al., 1999) ; (iii) cellular pre-mRNAs with unprocessed or incompletely processed 3Ј ends accumulates in cells infected by these mutant viruses (Chen et al., 1999; Shimuzu et al., 1999) ; and (iv) the NS1A protein is physically associated with 30-kDa CPSF in influenza A virusinfected cells (Nemeroff et al., 1998) . As a result of the inhibition of 3Ј-end processing, cellular mRNAs are not exported from the nucleus at early times after virus infection (Katze and Krug, 1984; Chen et al., 1999) .
To obtain definitive proof that the 30-kDa CPSF-NS1A protein interaction plays a crucial role in the viral posttranscriptional countermeasure against the early, IFN-␣/␤-independent cellular antiviral response, a recombinant influenza A/Udorn/72 virus was generated that encodes an NS1A protein which has an altered amino acid sequence centered around amino acid 186 and as a result does not bind the 30-kDa subunit of CPSF (Noah et al., 2003) . This recombinant virus (CPSF mutant virus) is substantially attenuated, indicating that this binding site in the NS1A protein is required for efficient virus replication. The effect of this NS1A mutation on the IFN-␣/␤-independent antiviral response was analyzed by infecting GRE cells with the CPSF mutant virus: cellular antiviral mRNAs are produced and translated as a result of the early IFN-␣/␤-independent activation of the transcription of cellular antiviral genes (Noah et al., 2003) . Consequently, this mutation in the NS1A protein relieves the inhibition of the posttranscriptional processing of these cellular antiviral pre-mRNAs that occurs in cells infected by wild-type virus, establishing that this viral countermeasure is largely mediated by the binding of the 30-kDa CPSF subunit to the NS1A protein. Thus, one of the major roles of the NS1A protein-mediated inhibition of the processing of newly synthesized cellular pre-mRNAs is the inhibition of the early, IFN-␣/␤-independent production of cellular antiviral mRNAs. The mechanism by which the NS1A protein interaction with 30-kDa CPSF enables influenza A virus to win the initial battle in the intracellular war between human cells and human influenza A virus is diagrammed in Fig. 2A .
Influenza B virus
Infection of human cells with influenza B virus also induces the IFN-␣/␤-independent activation of IRF-3 and transcription of ISRE-controlled cellular genes . This transcription results in the production of antiviral cellular mRNAs and antiviral proteins, in contrast to the situation in cells infected with influenza A virus . It is not surprising that the efficient production of functional cellular antiviral mRNAs occurs in influenza B virus-infected cells , because the NS1B protein does not bind either 30-kDa CPSF or PABII (Fig.  1B) and does not inhibit the posttranscriptional processing of cellular pre-mRNAs (Wang and Krug, 1996) .
Influenza B virus activates IRF-3 even when transcription by the virion-associated polymerase is blocked by prior ultraviolet light (UV) irradiation of the virus . Thus, influenza B virus may be similar to two DNA viruses, cytomegalovirus and herpes simplex virus, which activate the transcription of ISRE-controlled genes via an initial interaction of the virus with the cell surface, either the binding of virions to receptors on the cell surface or the subsequent entry of virions into the cell (Boyle et al., 1999; Chin and Cresswell, 2001; Preston et al., 2001; Simmen et al., 2001) . In contrast, UV-irradiation of influenza A virus abrogates its ability to activate IRF-3 , suggesting that transcription by the virion-associated polymerase is needed. Such viral transcription may generate virus-encoded, double-stranded RNA molecules, which have been postulated to be responsible for the activation of IRF-3 in cells infected by other negative-strand RNA viruses Reich, 1993, 1995; Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al., 1998; Guo et al., 2000; Iwamura et al., 2001) .
Because these early antiviral proteins are synthesized, subsequent countermeasures by influenza B virus would likely be needed. It is possible that one of the influenza B virus countermeasures is mediated by the unique ability of the NS1B protein to bind one of the predominant early antiviral proteins, the ISG15 protein (Yuan et al., 2002) , which is an ubiquitin-like protein Hass, 1992, 1994) . This binding results in the inhibition of conjugation of ISG15 to its target proteins in both in vitro and influenza B virus-infected cells (Yuan and Krug, 2001 ). The NS1B protein inhibits the first step in conjugation, which is catalyzed by an enzyme that was identified as UBE1L (Yuan and Krug, 2001 ). UBE1L was originally identified because its gene is deleted in many lung cancer cells (Carritt et al., 1992; Kok et al., 1993 Kok et al., , 1995 . The cellular and viral events that occur during the initial battle in the intracellular war between human cells and human influenza B virus are diagrammed in Fig. 2B . It has not yet been possible to determine how ISG15 conjugation affects the replication of influenza B virus, in large part because ISG15 conjugation occurs very slowly in all tissue culture cell lines that have been tested. Free ISG15 is produced for an extended period of time (for approximately 12-16 hs) before conjugation of ISG15 to its target proteins begins (Loeb and Haas, 1992; Yuan and Krug, 2001 ). Because of this delay, significant ISG15 conjugation does not occur until after most influenza B virus-specific events have already taken place. The delay in ISG15 conjugation may indicate that the ISG15 conjugation pathway is defective in these cell lines, and/or that the principal ISG15 deconjugating enzyme USP43 (Liu et al., 1999; Malakhov et al., 2002 ) is produced in excess in these cell lines. To elucidate the role of the NS1B proteinmediated inhibition of ISG15 conjugation, it will be necessary to identify the protein targets of ISG15 conjugation and to determine how ISG15 conjugation affects the activities of these target proteins.
Part of the ISG15 protein-binding site is located in one of the loops in the N-terminal binding domain of the NS1B protein (Yuan et al., 2002) . Because there are two copies of this loop, it is likely that two ISG15 protein molecules bind to each dimeric NS1B protein. The other part of the ISG15-binding site is in the 94 -103 amino acid region of the NS1B protein (Fig. 1B) . The function of the rest of the effector domain has not yet been determined. The presence of this particular loop in the NS1B RNA-binding domain enables the NS1B protein to carry out a biological function-the inhibition of ISG15 conjugation-that is not carried out by the NS1A protein whose RNA-binding domain lacks this loop (Yuan et al., 2002) . Thus, the N-terminal region of the NS1B protein binds not only dsRNA but also a specific cellular protein, and thus, differs from the corresponding region of the NS1A protein, which appears to function solely as a dsRNA-binding domain. Thus, the divergence of the NS1A and NS1B proteins results in differences in the functions of not only their effector domains but also their N-terminal domains.
Activation of PKR: a second virus-cell battle prior to the production of IFN-␣/␤
Another cellular antiviral response prior to the production of IFN-␣/␤ is mediated by protein kinase R (PKR), which can be activated by dsRNA or by interaction with specific proteins (Patel and Sen, 1998; Ito et al., 1999; Patel et al., 2000; D'Acquisto and Ghosh, 2001; Peters et al., 2001; Williams, 2001) . Substantial amounts of PKR and its mRNA are expressed constitutively in the absence of IFN-␣/␤ (Der et al., 1998; Williams, 2001) . Activated PKR phosphorylates the ␣-subunit of the translation initiation factor eIF2, resulting in the inhibition of protein synthesis and hence virus replication (reviewed in Safer, 1983) .
Influenza viruses
In cells infected by influenza A virus, the NS1A protein plays a major role in inhibiting the activation of PKR (Hatada et al., 1999; Bergmann et al., 2000) . It is not known whether the inhibition of constitutively expressed PKR by the NS1A protein is mediated by its RNA-binding domain. The RNA-binding domain is sufficient for the inhibition of PKR activation in vitro, but this inhibition requires a high concentration of the NS1A protein (Lu et al., 1995) , presumably due to the low affinity of the NS1A RNA-binding domain for dsRNA. This in vitro result does not establish that the low-affinity NS1A RNA-binding domain accesses dsRNA in vivo, where this domain has to compete with many cellular proteins that have higher affinities for dsRNA. In fact, the amino acids of the NS1A protein that have been implicated in the inhibition of PKR do not include those that bind directly to the dsRNA target (R38, K41) nor those that are required for the dimerization of the RNA-binding domain, but instead include an amino acid in the effector domain (Hatada et al., 1999) . Consistent with these results, it has been reported that the NS1A protein interacts directly with PKR to block its activation (Tan and Katze, 1998) . Nonetheless, it has not been ruled out that binding of dsRNA by the NS1A RNA-binding domain participates in the inhibition of PKR activation. More studies are needed to establish the mechanism by which the NS1A protein inhibits PKR activation in infected cells. It has not been determined whether the NS1B protein of influenza B virus plays a role in the inhibition of PKR activation.
The production of IFN-␣/␤: a third virus-cell battle
Infection of mammalian cells with many viruses also activates the transcription factors that induce the transcription of the IFN-␣ and IFN-␤ genes (Biron and Sen, 2001 ). The complex of transcription factors required for the induction of IFN-␤ transcription, which has been termed the enhanceosome, contains two of the factors present in the VAF, IRF-3 and IRF-7, NF-B plus additional factors Wathelet et al., 1998) . The IFN-␣/␤ protein molecules synthesized in initially infected cells are secreted and bind to cell-surface receptors to establish an antiviral state via the activation of transcription factors (Biron and Sen, 2001) . Activation results in the formation of a protein complex, called ISGF-3 (Darnell et al., 1994) , which differs from VAF. The ISGF-3 complex binds to all the ISREs of cellular genes, thereby inducing their transcription. Thus, some ISREs can bind both VAF and ISGF-3, whereas other ISREs can bind only the ISGF-3 that is activated by IFN-␣/␤ (Wathelet et al., 1992 . Secreted IFN-␣/␤ may not provide much protection to initially infected cells that produce IFN-␣/␤ because these cells already have an established virus infection. Rather, it is likely that the primary role of IFN-␣/␤ is to protect neighboring uninfected cells, thereby inhibiting virus spread. Viruses need to mount countermeasures to inhibit the production of IFN-␣/␤ by the cell. This is another key battle in the intracellular warfare between mammalian cells and mammalian viruses.
Influenza A virus
Many investigators have shown that IRF-3 and NF-B are activated, and that IFN-␣/␤ is produced in cells infected by influenza A virus (Issacs and Lindemann, 1957; Pahl and Baeuerle, 1995; Ronni et al., 1997; Flory et al., 2000; Matikainen et al., 2000; Hiscott et al., 2001; Huang et al., 2001; Julkunen et al., 2001; Geiss et al., 2002; Kim et al., 2002; Noah et al., 2003) . Microarray analysis of the cellular mRNAs produced after influenza A virus infection of human monocyte-derived dendritic cells established that IFN-␤1, and several IFN-␣ species, are produced (Huang et al., 2001) . Dendritic cells produce more IFN-␣/␤ than human lung epithelial cells during influenza A virus infection (Julkunen et al., 2001 ). Nonetheless, the synthesis of IFN-␤ mRNA in influenza A virus-infected human lung epithelial cells is readily detected by an RNase protection assay (Noah et al., 2003) , and microarray analysis, which is considerably less sensitive than the RNase protection assay, showed that a substantial number of IFN-induced mRNAs, specifically including MxA mRNA, are produced (Geiss et al., 2002) . As IFN-␤ transcription requires activated IRF-3 and NF-B Wathelet et al., 1998) , these results provide further evidence that these two transcription factors are activated during influenza A infection, in conflict with two studies (Talon et al., 2000; Wang et al., 2000) .
These results show that even in the presence of a functional 30-kDa CPSF-binding site in the wild-type NS1A protein, some IFN-␤ pre-mRNA escapes the inhibition of posttranscriptional processing mediated by this binding site. Some posttranscriptional processing of several other virusinduced cellular pre-mRNAs also occurs in wild-type influenza A virus-infected cells, as detected by microarray analysis, e.g., the production of cellular mRNAs involved in the STAT and apoptotic pathways (Geiss et al., 2001 (Geiss et al., , 2002 Huang et al., 2001 ). These observations suggest that the function of the NS1A-binding site for 30-kDa CPSF is regulated during wild-type virus infection. One possibility is that the inhibition of posttranscriptional processing of cellular pre-mRNAs is relieved as a result of the activation of the nuclear export signal (NES) of the NS1A protein (Li et al., 1998) . This NES, which comprises amino acids 137-146 of the NS1A protein (Fig. 1A) , does not function in transfected cells, but is activated during virus infection. Activation of the NS1A NES might cause the nuclear export of those NS1A protein molecules that were imported into the nucleus at early times of infection, thereby eliminating the inhibition caused by the NS1A binding to at least some CPSF molecules. It is not clear why this would be advantageous for the virus. Perhaps cytoplasmic accumulation of the NS1A protein is needed to inhibit PKR activation.
Because mutation of the 30-kDa CPSF-binding site in the NS1A protein eliminates the inhibition of posttranscriptional processing of cellular pre-mRNAs throughout infection, it is not surprising that the production of IFN-␤ mRNA is enhanced in human lung epithelial cells infected by the CPSF mutant virus. The enhanced production of IFN-␤ would be expected to induce an antiviral state in neighboring uninfected cells more rapidly and more efficiently, thereby contributing to the attenuation of the CPSF mutant virus. Because the NS1A protein encoded by the CPSF mutant virus retains the binding site for the PABII protein, the cellular mRNAs synthesized in cells infected by this mutant virus should contain short poly(A) tails approximately 10 nucleotides in length. It is reasonable to expect that cellular mRNAs containing full-length poly(A) tails would be exported into the cytoplasm more efficiently, would be more stable, and/or would be translated more efficiently. Consequently, it would be predicted that an influenza A virus encoding an NS1A protein which contains mutated binding sites for both 30-kDa CPSF and PABII would be more attenuated than the CPSF mutant virus. Conversely, we would predict that reduced production of IFN-␤ mRNA would increase the virulence of influenza A virus. Reduction in IFN-␤ mRNA production would be expected if the NS1A protein-mediated inhibition of the posttranscriptional processing of cellular pre-mRNAs were maintained throughout infection. Thus, this key battle in the intracellular war between influenza A virus and human cells is a delicately regulated contest that most likely ends in a victory for the cell because the amount of IFN-␤ mRNA that escapes the NS1A protein-mediated inhibition of posttranscriptional processing limits virus spread to a tolerable level.
Influenza B virus
Definitive studies have not been reported on the synthesis of IFN-␣/␤ mRNA during infection by influenza B virus. We have found that IFN-␤ mRNA is synthesized in influenza B virus-infected cells (Min, J.-Y. and Krug, R.M., unpublished experiments). This is not surprising considering that the NS1B protein of influenza B virus does not inhibit the posttranscriptional processing of cellular mRNAs (Wang and Krug, 1996) .
The virus-cell battle after the production of IFN-␣/␤
The IFN-␣/␤ produced in initially infected cells protects neighboring uninfected cells against virus infection. Treatment of human cells with IFN-␣/␤ stimulates the transcription of several hundred human genes (Der et al., 1998) , resulting in at least an equivalent number of IFN-induced proteins, many of which participate in the antiviral response (Der et al., 1998; Stark et al., 1998) .
Influenza viruses
The replication of influenza A virus is inhibited in IFN-␣/␤-treated human cells in a dose-dependent manner (Ronni et al., 1997) . At the highest level of IFN-␣/␤ used, replication is almost completely inhibited. One of the IFN-␣/␤-induced gene products in human cells is the MxA protein, which has been shown to be largely responsible for the IFN-␣/␤-induced inhibition of influenza A virus replication (Pavlovic et al., 1990 (Pavlovic et al., , 1992 Ronni et al., 1997) . We have found that influenza B virus is also almost completely inhibited in IFN-␣/␤-treated human cells (Min, J.-Y. and Krug, R.M., unpublished experiments) . Consequently, the NS1A and NS1B proteins do not protect influenza A and B viruses, respectively, against the IFN-␣/␤-mediated antiviral response of human cells, and influenza A viruses (with one apparent exception described below) and influenza B viruses lose this battle and the war between human cells and the virus.
However, one NS1A protein apparently behaves differently: the NS1A protein of the highly pathogenic virus that was transmitted from chickens to humans in Hong Kong in 1997 protects the virus against the antiviral proteins produced in pig cells after IFN treatment (Seo et al., 2002) . Such protection requires the presence of glutamic acid at position 92 in the effector domain of the NS1A protein (see Fig. 1A ). The mechanism of this protection has not been established, and it is not known whether similar protection occurs in human cells. Future studies on this protection mechanism may be expected to elucidate additional functions of the NS1A protein in the virus-cell intracellular war.
A different interpretation of the intracellular war
Despite all the evidence that the influenza virus NS1A and NS1B proteins are multifunctional proteins, one group of investigators has argued that these proteins have only a single required function, namely the binding of dsRNA by the NS1 RNA-binding domain (summarized in Garcia-Sastre, 2001 ). These investigators generated mutant influenza A viruses that express NS1A proteins containing large Cterminal deletions. The most extensively studied mutant virus encodes a NS1A protein that is 124 -126 amino acids long and consequently contains the RNA-binding domain and 51-53 amino acids of the effector domain (see Fig. 1A ). Conflicting results have been reported concerning the growth of this mutant virus in tissue culture cells containing intact IFN-␣/␤ genes: highly attenuated growth in MDCK (canine kidney) cells ; but little or no attenuation in MDBK (bovine kidney) cells . Attenuation of virus growth is consistent with the microarray results obtained by this group of investigators using human epithelial lung cells (Geiss et al., 2002) . This analysis showed that the amount of IFN-␣/␤-induced cellular mRNAs produced during infection by this mutant virus was substantially increased compared to that produced by wild-type influenza A virus. The results with the CPSF mutant virus (Noah et al., 2003) explain these microarray data. Because the truncation of the NS1A protein removes the binding site for the 30-kDa subunit of CPSF, posttranscriptional processing of IFN-␤ pre-mRNA would not be inhibited throughout infection, resulting in increased production of IFN-induced mRNAs.
These investigators also inoculated inbred mice with the mutant influenza A viruses that express NS1A proteins containing large C-terminal deletions . Mice are not naturally infected with influenza viruses, but can be experimentally infected with mouse-adapted influenza virus strains (Wright and Webster, 2001 ). In addition, it is necessary to use inbred mice strains that lack a functional Mx gene, because the IFN-␣/␤-induced Mx protein mediates selective resistance to influenza virus and as a result influenza virus replication is blocked (Staehli and Haller, 1987) . Whereas cells from Mx-positive mice develop an efficient antiviral state against influenza virus after IFN-␣/␤ treatment (ϳ10 4 -fold reduction in virus yield), cells from Mx-negative mice are only weakly resistant to influenza virus after IFN-␣/␤ treatment (ϳ10-fold reduction in virus yield) (Staehli et al., 1984) . Consequently, inbred Mx-negative mice possess a defective innate immune system against influenza virus. These investigators found that mutant viruses encoding either a 126 amino acid long NS1A protein or a 73 amino acid long NS1A protein was attenuated in Mx-negative mice, and that the addition of short heterologous dimerization domains to the carboxy end of the truncated NS1A proteins partially relieved this attenuation . They claim that these results indicate that the primary function of the effector domain in these inbred mice is to stabilize the NS1A protein by providing an additional dimerization domain.
It remains to be established that these results with Mxnegative inbred mice portray the roles of the NS1A protein in countering cellular antiviral responses during influenza A virus infections of natural hosts, including humans. The effector domain of the NS1A protein that has evolved for these natural infections contains 157-164 amino acids, which have already been shown to be grouped into several specific functional sequences, namely, a NES and binding sites for two cellular 3Ј-end processing factors, 30-kDa CPSF and PABII (Li et al., 1998 (Li et al., , 2001 Nemeroff et al., 1998; Chen et al., 1999; Chen and Krug, 2000) . It is extremely unlikely that these effector domain functions would have been preserved during virus evolution if the primary, or sole, role of the effector domain was the provision of a short dimerization region to stabilize the 73 amino acid RNA-binding domain. Undoubtedly, one of the important selective pressures during the evolution of these effector domain functions for human infections has been provided by the IFN-induced human MxA gene, whose mouse counterpart is absent in the inbred mice experiments described above. In addition, it has been established that these conserved effector domain functions operate during influenza A virus infection of human cells. For example, as already discussed, the 30-kDa binding site of the NS1A protein mediates the inhibition of the posttranscriptional processing of cellular pre-mRNAs that plays key roles in the viral countermeasures against human antiviral responses ( Nemeroff et al., 1998; Chen et al., 1999; Shimuzu et al., 1999; Noah et al., 2003) . In contrast, the specific function of the low-affinity RNA-binding domain of the NS1A protein during virus infection remains elusive. This RNA-binding domain does not play a role in the inhibition of the posttranscriptional processing of cellular pre-mRNAs (Li et al., 1998) and does not prevent the activation of either IRF-3 or NF-B by sequestering dsRNA (Pahl and Baeuerle, 1995; Ronni et al., 1997; Flory et al., 2000; Hiscott et al., 2001; Kim et al., 2002; Noah et al., 2003) . Finally, it is not known whether the inhibition of PKR activation by the NS1A protein (Hatada et al., 1999; Bergmann et al., 2000) is mediated by its RNA-binding domain. Nonetheless, it is likely that the evolutionary conserved RNA-binding domain does carry out at least one essential function during virus infection, which remains to be identified.
Concluding remarks
Considerable progress has been made in understanding the multiple activities of the influenza virus NS1A and NS1B proteins and how these activities function in countering cellular antiviral responses. It has already been established that the functions of the NS1A protein of influenza A virus differ markedly from those of the NS1B protein of influenza B virus, resulting in major differences in the mechanisms by which these two proteins mediate viral countermeasures against cellular antiviral responses. In fact, this may be the greatest difference in function between influenza A and B virus proteins. These differences in the functions of the NS1A and NS1B proteins may be the basis for many of the differences in the biological properties, host range, and pathogenicity of these two influenza viruses. Many intriguing questions remain about the roles of the NS1A and NS1B proteins in the intracellular was between human influenza viruses and human cells.
